Status and phase
Conditions
Treatments
About
Participants will receive study treatment with agenT-797, botensilimab, balstilimab, ramucirumab, and paclitaxel. When participants start each agent will depend on how their disease is affecting them.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Table 2. Organ function requirements for eligibility Hematological Absolute neutrophil count: ≥1000/mcL Platelets: ≥90,000/mcL Hemoglobin: ≥8 g/dL Renal Serum creatinine: ≤1.5X ULN Hepatic Serum total bilirubin: ≤1.5X ULN OR Direct bilirubin ≤ULN for subjects with total bilirubin levels >1.5X ULN, except patients with Gilbert's disease (≤3X ULN) AST and ALT: ≤2.5X ULN Albumin: ≥3 mg/dL
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
37 participants in 1 patient group
Loading...
Central trial contact
Geoffrey Ku, MD; Yelena Janjigian, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal